TB-500 (Thymosin Beta-4) · Research brief
Thymosin Alpha-1 In Vitro Study: Preclinical Evidence
Short answer
A thymosin alpha-1 in vitro study is, in nearly every published case, a cell-culture experiment that asks a narrow question: what changes in immune cell signaling, surface phenotype, cytokine output or survival when cultured cells are exposed to this 28 amino acid thymic peptide. The preclinical record sits in two tiers.
A thymosin alpha-1 in vitro study is, in nearly every published case, a cell-culture experiment that asks a narrow question: what changes in immune cell signaling, surface phenotype, cytokine output or survival when cultured cells are exposed to this 28 amino acid thymic peptide. The preclinical record sits in two tiers. The first is cultured-cell work, concentrated on dendritic cells, monocytes, lymphocytes and, more recently, epithelial lines, which maps receptor engagement and the transcriptional response that follows. The second is animal model work, overwhelmingly in mice, which tests whether those cellular shifts appear as measurable host responses during infection challenge, induced immune suppression or tumor growth. Real Peptides supplies Thymosin Alpha-1 as a research-use-only compound. This page summarizes what the two tiers report, how the models are built, where the findings are contested, and which questions the published literature has not answered.
What does a thymosin alpha-1 in vitro study usually measure?
Most cell-culture work on this peptide measures immune activation state rather than direct cytotoxicity or receptor binding affinity. The common readouts fall into four families. Cytokine output is measured in culture supernatants by enzyme-linked immunosorbent assay or multiplex bead panels, with interleukin-2, interleukin-12, interferon gamma, tumor necrosis factor alpha and interleukin-10 appearing most often as the reported analytes. Surface phenotype is read by flow cytometry, typically costimulatory molecules and major histocompatibility complex class II on antigen-presenting cells, and activation or exhaustion markers on lymphocytes. Transcriptional response is read by quantitative polymerase chain reaction or, in newer papers, by RNA sequencing of exposed cultures against vehicle-matched controls. Functional endpoints include proliferation assays using dye dilution or metabolic indicators, killing assays for natural killer cell preparations, and phagocytosis assays for monocyte-derived cells.
The cell systems are similarly consistent across the literature. Human peripheral blood mononuclear cells and monocyte-derived dendritic cells are used for translational relevance, murine bone marrow-derived dendritic cells and splenocytes for mechanistic work that can be paired with knockout strains, thymocyte preparations for maturation questions, and tumor or airway epithelial lines where the research question concerns non-immune cells. Experiments are generally built as a concentration series across several orders of magnitude with a matched vehicle arm and a positive control such as a defined Toll-like receptor agonist.
The limits of this evidence tier are worth stating plainly. Culture systems strip out the serum proteases, clearance and tissue architecture that shape peptide exposure in a living animal, so the concentrations at which effects appear in a dish do not map cleanly onto anything in vivo. Donor-to-donor variability in primary human cells is substantial, and serum-containing media can mask or exaggerate effects depending on protein binding. Research suggests the peptide's actions are context dependent, which means the baseline activation state of the culture is itself an experimental variable rather than a nuisance.
What is Thymosin Alpha-1 at the molecular level, and why does that shape assay design?
Thymosin Alpha-1 is a 28 amino acid, N-terminally acetylated peptide corresponding to the N-terminal region of the larger nuclear protein prothymosin alpha, and it was originally characterized from a thymic tissue fraction. It is strongly acidic, highly hydrophilic and, in plain aqueous buffer, largely unstructured. Biophysical studies report that it adopts partial helical character in membrane-mimetic or structure-promoting solvent conditions, which is one reason the literature has struggled to pin down a single high-affinity receptor and a co-crystal structure. The compound is commonly listed under CAS number 62304-98-7 and has a molecular mass near 3.1 kilodaltons.
Those properties have direct consequences for experimental design, and they explain several recurring features of the published assays. Because the molecule carries substantial negative charge and lacks a hydrophobic core, nonspecific adsorption to labware is less of a problem than it is for lipophilic peptides, but proteolytic clipping in serum-containing media is a real concern across long incubations, which is why many papers report short time courses or repeated exposure in longer cultures. Because the peptide has no classical pharmacologically defined single receptor in the way a hormone analog does, mechanistic papers lean on pathway blockade, knockout cells and reporter constructs rather than on binding displacement curves.
The lack of a defined structured binding pocket also shapes how the field interprets negative results. A culture that shows no response may simply lack the receptor repertoire or the priming signal required for the peptide to act, rather than demonstrating that the peptide is inert. The literature describes this compound as an immunomodulator whose output depends on the state of the responding cell, so in vitro panels in modern papers tend to include both resting and stimulated conditions. Researchers sourcing material for this kind of work generally verify molecular identity and the listed CAS number before procurement, since sequence-adjacent fragments and non-acetylated variants will not behave identically in these assays.
How does the peptide engage Toll-like receptor signaling in cultured cells?
The best-developed mechanistic account in the cell-culture literature is that Thymosin Alpha-1 acts through Toll-like receptor signaling on antigen-presenting cells rather than through a dedicated orphan receptor. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling, published in Blood in 2004, reported that exposure of dendritic cells to the peptide produced an activation profile consistent with Toll-like receptor engagement, with the response depending on the adaptor protein MyD88 in cells taken from knockout mice, and that the resulting cells supported a type 1 helper T cell response relevant to antifungal host defense. Subsequent work in the broader literature has attributed activity to Toll-like receptor 2 and Toll-like receptor 9 depending on the cell type and species studied.
The mechanism, as the literature describes it, runs from receptor engagement through MyD88 to nuclear factor kappa B and interferon regulatory factor activity, with downstream transcription of interleukin-12 family members and costimulatory molecules. That framing matters because it predicts the pattern seen in many papers: the peptide behaves less like a classical agonist with a steep concentration-response curve and more like a conditioning signal that shifts how a cell responds to a second stimulus.
There is an unavoidable methodological caveat here, and the more careful papers address it directly. Toll-like receptor readouts are exquisitely sensitive to bacterial endotoxin, and any peptide preparation carries a contamination question. Studies that report Toll-like receptor-dependent effects without an endotoxin control, a polymyxin B neutralization arm, or a heat or protease inactivation comparison are difficult to interpret, because a trace lipopolysaccharide burden would produce a similar activation signature through the same adaptor. This is the single most common reason that cell-culture findings in this area fail to reproduce across laboratories, and it is a sound argument for verifying the identity and quality documentation of any research material before an endotoxin-sensitive experiment. Real Peptides publishes independent third-party certificates of analysis for every batch at /coas/.
What do dendritic cell and T cell culture models report?
Dendritic cells are the most frequently studied target in the cell-culture literature, and the reported effect is a shift in maturation and polarizing capacity rather than wholesale activation. Studies report that exposed dendritic cell cultures show increased expression of costimulatory surface molecules and increased interleukin-12 output, and that such cells, when placed into co-culture with naive T cells, favor interferon gamma-producing type 1 helper responses. Later work from the same research program described a second and partly opposing arm, in which the peptide promotes tryptophan catabolism through indoleamine 2,3-dioxygenase, generating a regulatory tone that restrains inflammation. The literature frames these two observations as complementary rather than contradictory, describing a compound that pushes toward a balanced response rather than toward maximal activation.
T cell work divides into maturation studies and restoration studies. Maturation studies use thymocyte or immature precursor preparations and ask whether the peptide accelerates acquisition of mature surface markers, which is the original rationale for a thymic peptide fraction. Restoration studies use lymphocytes drawn from immunosuppressed animals, from aged donors or from cultures rendered hyporesponsive in vitro, and ask whether proliferative and cytokine responses recover in exposed arms relative to vehicle arms. Research suggests that effects are easier to detect in suppressed or exhausted cultures than in healthy, fully responsive cells, which fits the conditioning-signal model described above.
The limitations of this section of the literature are real. Many of the foundational T cell observations come from older papers with small replicate counts, limited phenotyping by the standards of modern flow cytometry, and reporting conventions that predate routine deposition of raw data. Primary human cell experiments carry donor variability that can exceed the effect size under study unless the design is paired. And co-culture readouts conflate direct peptide action on T cells with indirect action through the antigen-presenting cell, which is why transwell and conditioned-medium controls appear in the better-designed studies.
What do macrophage, monocyte and natural killer cell assays show?
Innate effector assays form a smaller but consistent part of the in vitro record, and they generally report functional enhancement rather than phenotype switching alone. Monocyte and macrophage studies measure phagocytic uptake of labeled particles or microorganisms, oxidative burst, and polarization markers that distinguish inflammatory from reparative states. The literature describes shifts in polarization marker expression in exposed cultures and, in some tumor-adjacent models, a move away from the reparative phenotype associated with permissive tumor microenvironments. These findings are reported as modest and context dependent rather than as switch-like effects.
Natural killer cell work typically uses cytotoxicity assays against standard target lines, read by chromium release in older papers and by flow cytometry-based viability or degranulation markers in newer ones. Studies report increased killing capacity in exposed preparations under some conditions, often in cells drawn from suppressed donors or animals, and the effect is frequently described as requiring an accessory cell population, which again points to indirect action through cytokine intermediaries rather than a direct receptor on the effector cell.
The interpretive caution for this tier is that innate functional assays have wide dynamic ranges and are sensitive to handling. Target-to-effector ratios, incubation length, the exact labeling chemistry and the freshness of primary cells all move the baseline. Published effects in this area are usually reported as fold-change against a same-day vehicle arm for that reason, and cross-study comparison of absolute values is not meaningful. The broader point for anyone reading this literature is that the innate findings are supportive rather than foundational: they are consistent with the dendritic cell mechanism but do not independently establish it.
What has in vitro work suggested about epithelial cells and the cystic fibrosis model?
The most prominent non-immune cell-culture claim for this peptide came from cystic fibrosis research. Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis, published in Nature Medicine in 2017, reported that the peptide acted on two axes at once in cell and mouse models, reducing inflammatory signaling and improving the maturation and function of the mutant cystic fibrosis transmembrane conductance regulator protein. The cell work used airway epithelial models carrying the common F508del variant, with electrophysiological and protein maturation readouts, and the mouse work used an established disease model with inflammatory endpoints.
The mechanism proposed was that a single small peptide could address both the inflammatory component and the protein-folding component of the disease model, which would be unusual and which is exactly why the paper attracted attention. It is also why the finding should be read alongside what came afterward. Independent groups subsequently attempted to reproduce the channel-function results in comparable epithelial systems, and the replication record published in the years following has been mixed enough that the field does not treat the protein-correction claim as settled. Researchers planning work in this area are generally expected to read the follow-up correspondence in the primary literature rather than citing the original report alone.
This episode is instructive beyond cystic fibrosis. It illustrates how sensitive epithelial assays of channel function are to culture conditions, differentiation state at air-liquid interface, and the specific cell line or primary donor material used. It also illustrates the general pattern of the preclinical record for this compound: striking single-laboratory findings appear periodically, and the ones that survive independent replication tend to be the immunological observations rather than the mechanistic claims about non-immune targets.
Which animal models appear most often in a thymosin alpha-1 animal study?
Mice dominate the in vivo literature, and the designs cluster into five recognizable families. The first is the induced immune suppression model, in which animals are rendered leukopenic by a cytotoxic agent and the peptide arm is compared with a vehicle arm on immune cell recovery, spleen and lymph node cellularity, and ex vivo lymphocyte responsiveness. The second is the infection challenge model, in which animals are inoculated with a fungal, viral or bacterial pathogen and the endpoints are survival curves, organ colony counts and histopathology. The third is the sepsis model, usually built by cecal ligation and puncture or by endotoxin challenge, with survival and systemic cytokine profiles as endpoints. The fourth is the tumor model, either syngeneic in immunocompetent strains or xenograft in immunodeficient strains, with tumor volume curves, survival and immune infiltrate characterization. The fifth is the organ injury model, most often chemically induced liver injury, with histological scoring and serum chemistry endpoints.
Across these designs the reporting conventions are similar. Study arms are defined by assigned amounts of peptide against a vehicle-matched control, group sizes are typically small by modern statistical standards, and the follow-up windows are short. Rats appear less often, usually in pharmacokinetic or tolerability work rather than in efficacy models. Non-rodent species are rare in the published efficacy literature.
Two cross-species caveats matter for anyone reading this body of work. Toll-like receptor repertoires and ligand specificities differ between mice and humans, which is a direct problem for a compound whose leading mechanism is Toll-like receptor dependent. And the peptide is cleared quickly from circulation, so in vivo exposure windows are narrow and the relationship between an assigned amount in an animal arm and a sustained tissue concentration is not straightforward. The literature generally reports outcomes at the level of the study arm rather than attempting exposure-response modeling.
What do rodent infection and immunosuppression models report?
The infection literature is where the in vivo evidence is strongest, and it is closely tied to the dendritic cell mechanism described in the cell-culture work. The Blood 2004 report paired its culture findings with mouse work in a fungal challenge setting, describing improved type 1 helper resistance in peptide arms. Other published models in the broader literature have used fungal, viral and bacterial challenges, with survival and pathogen burden as the primary endpoints and with immune phenotyping of spleen or draining lymph node cells as supporting evidence. Studies report that effects are most visible when the host immune compartment has been compromised first, which is consistent with the in vitro observation that suppressed cells respond more than healthy ones.
Immunosuppression models are structurally simpler. An agent is used to deplete the immune compartment, the peptide arm and the vehicle arm are followed, and recovery of cell counts and ex vivo function is compared. The literature describes faster or more complete recovery of lymphocyte populations in peptide arms in several such models. These studies are useful mechanistically because they isolate the reconstitution question from the pathogen question, but they are also prone to a floor effect: a profoundly depleted animal has a large window in which any recovery signal looks impressive relative to an untreated control.
The methodological limits are consistent across this literature. Group sizes are often under ten animals per arm. Blinding and randomization are inconsistently reported in older papers. Survival endpoints in challenge models are highly sensitive to inoculum size, strain background and husbandry conditions, which means that absolute survival figures are not portable between laboratories. The appropriate reading is directional: the models consistently point the same way on immune reconstitution and infection resistance, while the magnitude of any individual reported effect should be treated as model specific.
What does the animal tumor immunology literature describe?
Tumor model work with this peptide has been published for several decades and is best read as exploratory immunomodulation research rather than as oncology efficacy data. The designs use syngeneic tumor lines implanted into immunocompetent mice, where an immune-mediated effect is possible, or human tumor xenografts in immunodeficient mice, where it largely is not and where any signal must come from residual innate immunity or from a direct effect on the tumor cell. Endpoints are tumor growth curves, survival, and in newer papers, flow cytometric or immunohistochemical characterization of the immune infiltrate.
Two mechanistic claims recur. The first is that exposure increases major histocompatibility complex class I expression on tumor cells in culture, which would make them more visible to cytotoxic lymphocytes, and that this translates into greater immune infiltration in vivo. The second is that the peptide shifts tumor-associated macrophage phenotype away from the reparative, permissive state. Both claims appear in the literature with supporting data, and both are reported as modest effects that are more pronounced when the peptide arm is combined with another immunologically active agent than when it is used alone.
The weaknesses here are the familiar ones for the field. Combination arms make attribution difficult, since an additive signal in a combination model does not establish an independent mechanism. Many of the older papers predate current standards for reporting randomization, blinding and exclusion criteria. Xenograft results cannot speak to an immune mechanism by construction. And publication bias in a literature built largely around a single compound family is a reasonable concern. The honest summary is that the animal tumor immunology work is hypothesis-generating, internally consistent with the dendritic cell mechanism, and insufficient on its own to support claims beyond the models tested.
Is there published research on thymosin alpha 1 for dogs?
The peer-reviewed canine-specific literature on this peptide is sparse, and the searches that bring people to the question of thymosin alpha 1 for dogs are usually veterinary in origin rather than grounded in a body of published canine trials. What exists is best described as scattered: dogs appear in the wider immunology and safety literature as a non-rodent species, and veterinary immunology reviews discuss thymic peptides as a class, but there is no large, replicated canine efficacy literature comparable to the mouse record described above. Anyone searching for canine data should expect to find case reports, small veterinary series and extrapolation from rodent work rather than controlled studies.
From a research design standpoint, a credible canine study would need several things that the current literature largely lacks. Species-matched reagents are the first requirement, since cytokine detection antibodies and flow cytometry panels validated for human or mouse cells do not reliably cross-react with canine targets. Canine Toll-like receptor biology differs from both mouse and human biology in ligand specificity and expression pattern, which is directly relevant for a compound whose mechanism is receptor dependent in that family. Canine peripheral blood mononuclear cell assays are feasible and would be the logical first step, establishing whether the activation signature seen in human and murine cultures is reproducible in canine cells before any in vivo design is considered.
The practical position is simple. Real Peptides supplies research-use-only material and does not provide veterinary, clinical or use guidance of any kind. Research involving companion animals or purpose-bred canines falls under institutional animal care and use oversight and under veterinary licensure in the relevant jurisdiction, and those frameworks, not a supplier, govern what may be done. The canine question is answered here as a literature question because that is the only way it can responsibly be answered.
How do Thymosin Alpha-1 and Thymosin Beta-4 differ in preclinical work?
Despite the shared name, the two thymosins are unrelated molecules with separate literatures, and conflating them is one of the more common errors in secondary summaries. Thymosin Alpha-1 is a 28 amino acid acidic peptide studied almost entirely as an immune modulator acting on antigen-presenting cells. Thymosin Beta-4 is a 43 amino acid actin-sequestering protein whose preclinical literature concerns cell migration, angiogenesis and tissue repair. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair, published in Nature in 2004, is the foundational report for that second line of work, describing migration and survival effects in cardiac cell models and repair endpoints in a mouse model.
The practical consequence is that the two compounds call for entirely different assay panels. Alpha-1 work is built around cytokine and phenotype readouts in immune cells, with Toll-like receptor pathway controls. Beta-4 work is built around scratch and transwell migration assays, actin polymerization measurements, tube formation assays for endothelial models, and histological repair scoring in vivo. A laboratory planning comparative work on the thymosin family should expect to run two distinct protocols rather than one shared design, and the fragment marketed under the code TB-500 is a related but distinct research material rather than a synonym for the full-length protein studied in the Nature report.
Real Peptides lists both compounds as separate research-use-only catalog items, including TB-500 Thymosin Beta-4, and the full research catalog is available at /shop/. Verifying which molecule a given reference actually studied, by sequence length and by the exact compound name in the paper title, is the single most useful habit when reading across the thymosin literature.
How is concentration handled in laboratory planning, and does Real Peptides provide preparation guidance?
Real Peptides does not provide preparation, handling or use guidance for any catalog compound, because these are research-use-only materials and the experimental design belongs to the investigating laboratory and its oversight body. What can be described factually is the concentration framework that the published literature uses, which is straightforward mass-per-volume arithmetic.
In vitro papers report exposure as a concentration in the culture well, expressed in micrograms per milliliter or in molar units, and converting between the two requires only the molecular mass of the peptide, which for this compound is near 3.1 kilodaltons. A stock solution is described in the methods section by its mass per volume, commonly in milligrams per milliliter, and the working concentration in the assay is a stated dilution of that stock into culture medium.
Animal studies in this literature report exposure by study arm, naming the assigned amounts for each arm and the vehicle used for the control arm. Those parameters belong to the individual study protocol and to the institutional approval that governed it, and they are reported here only as a description of how the literature is written, not as guidance of any kind.
Two points about the framework are worth stating for anyone reading methods sections critically. First, the concentration a paper reports is the nominal concentration added to the well, not the free peptide concentration available to the cells, which will be lower in serum-containing media and lower still across a long incubation given proteolysis. Second, molar and mass units are not interchangeable across the thymosin family, because the two major thymosins differ substantially in length and mass, so comparisons between alpha and beta literature on a microgram basis are not meaningful.
How do researchers verify peptide identity before a preclinical experiment?
Identity verification before procurement is a routine part of preclinical planning, and for a peptide of this kind it rests on three checks. The first is the registry identifier: confirming that the compound listed matches the CAS number commonly assigned to Thymosin Alpha-1 and that the stated sequence length and N-terminal acetylation match the molecule described in the literature being replicated. The second is analytical documentation: a certificate of analysis for the specific lot, generated by an independent laboratory, showing identity confirmation by mass spectrometry and chromatographic analysis. The third is lot traceability, meaning that the certificate can be matched to the physical material received rather than representing a generic product-level document.
This matters more for this compound than for many others, for a mechanistic reason already discussed. Because the leading mechanism runs through Toll-like receptor signaling, and because those assays respond strongly to bacterial endotoxin, the provenance and analytical history of the material is not a bureaucratic detail but an experimental variable. A result that cannot be attributed confidently to the peptide rather than to a contaminant is not a usable result, and the controls that distinguish the two cost time that is better spent on the actual question.
Real Peptides supplies research-use-only compounds and publishes independent third-party certificates of analysis for every batch at /coas/, and information about where the company operates is published at /location/. Those documents are the appropriate starting point for a laboratory's own incoming material verification, which typically continues with whatever internal confirmation the institution's quality system requires. No supplier documentation substitutes for the receiving laboratory's own controls, and the published record on this compound gives several concrete reasons why those controls matter.
What are the main limitations of the preclinical evidence base?
The honest summary of this literature is that it is broad, internally consistent in direction, and thin in independent replication at the level of specific mechanistic claims. Five limitations recur. First, much of the foundational work is old, with reporting standards that predate routine disclosure of randomization, blinding, exclusion criteria and effect sizes with confidence intervals. Second, a substantial fraction of the mechanistic literature originates from a small number of research programs, which raises the usual question about independent confirmation. Third, the Toll-like receptor mechanism that unifies the field is also the mechanism most vulnerable to endotoxin artifact, and not every published report controls for it adequately. Fourth, the species gap is real: mouse and human Toll-like receptor biology differ in ways that matter for this compound specifically. Fifth, the cystic fibrosis episode demonstrates that high-profile findings in non-immune systems have proven difficult to reproduce.
There are also gaps rather than weaknesses. No well-characterized single high-affinity receptor has been established, which limits the field's ability to design selective probes or to interpret negative results. Exposure-response relationships in animal models are poorly characterized because of rapid clearance and because most studies report arm-level outcomes rather than measured tissue exposure. Comparative work across species, including canine models, is largely absent. And the interaction between the activating arm of the mechanism and the regulatory, tryptophan catabolism arm has not been resolved into a predictive model of when the compound pushes toward inflammation and when it restrains it.
None of this makes the literature unusable. It means that the compound should be read as a well-documented immunomodulatory research tool with a plausible receptor-level mechanism and a long but uneven experimental record, not as a settled pharmacology.
What questions remain open for new preclinical work?
Several questions sit open in a way that a well-designed study could address. The first is receptor-level specificity: whether the Toll-like receptor dependence reported in dendritic cells reflects direct engagement, indirect modification of another ligand's activity, or a conformational effect that depends on the membrane environment the peptide encounters. Reporter cell lines expressing defined single receptors, paired with rigorous endotoxin controls, are the standard tool for that question.
The second is the balance question. The literature describes both an activating arm and a regulatory arm, and the conditions that determine which predominates have not been mapped systematically. A factorial design across priming states, cell types and concentration ranges, with matched transcriptional readouts, would be more informative than another single-condition activation report.
The third is cross-species validation. Given how much of the mechanism rests on a receptor family with known species differences, parallel assays in human, murine and canine primary cells using species-matched reagents would clarify how much of the mouse record should be expected to transfer. That work would also provide the missing foundation for any future canine model.
The fourth is exposure characterization in vivo. Animal studies in this literature overwhelmingly report outcomes by study arm without measured tissue or plasma exposure, which makes it impossible to relate in vitro concentration thresholds to in vivo observations. Studies pairing outcome endpoints with measured exposure would let the two evidence tiers speak to each other.
The fifth is replication of the contested findings. The epithelial and channel-function claims remain unresolved, and a multi-laboratory replication using shared protocols and shared material lots would settle a question the field has left open for years. Each of these is a tractable study, and each would do more for the evidence base than another descriptive report in an already well-covered model.
All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.
References
- Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004. PMID: 14982877
- Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nature Medicine. 2017. PMID: 28394330
- Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. PMID: 15565145
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add vials.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA